

# Bart Clarke

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4216256/publications.pdf>

Version: 2024-02-01

90  
papers

8,608  
citations

66315

42  
h-index

53190

85  
g-index

103  
all docs

103  
docs citations

103  
times ranked

10154  
citing authors

#	ARTICLE	IF	CITATIONS
1	Normal Bone Anatomy and Physiology. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2008, 3, S131-S139.	2.2	1,423
2	Vitamin D Insufficiency. <i>Mayo Clinic Proceedings</i> , 2011, 86, 50-60.	1.4	613
3	Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research. <i>Journal of Bone and Mineral Research</i> , 2016, 31, 16-35.	3.1	491
4	Hypoparathyroidism in the adult: Epidemiology, diagnosis, pathophysiology, target-organ involvement, treatment, and challenges for future research. <i>Journal of Bone and Mineral Research</i> , 2011, 26, 2317-2337.	3.1	485
5	American Association of Clinical Endocrinologists and American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis – 2016–Executive Summary. <i>Endocrine Practice</i> , 2016, 22, 1111-1118.	1.1	453
6	Primary hyperparathyroidism: review and recommendations on evaluation, diagnosis, and management. A Canadian and international consensus. <i>Osteoporosis International</i> , 2017, 28, 1-19.	1.3	376
7	Current Issues in the Presentation of Asymptomatic Primary Hyperparathyroidism: Proceedings of the Fourth International Workshop. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 3580-3594.	1.8	318
8	Management of Hypoparathyroidism: Summary Statement and Guidelines. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 2273-2283.	1.8	303
9	Efficacy and safety of recombinant human parathyroid hormone (1-84) in hypoparathyroidism (REPLACE): a double-blind, placebo-controlled, randomised, phase 3 study. <i>Lancet Diabetes and Endocrinology</i> , 2013, 1, 275-283.	5.5	244
10	Epidemiology and Diagnosis of Hypoparathyroidism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 2284-2299.	1.8	230
11	Physiology of Bone Loss. <i>Radiologic Clinics of North America</i> , 2010, 48, 483-495.	0.9	208
12	Androgens and bone. <i>Steroids</i> , 2009, 74, 296-305.	0.8	198
13	The Pathophysiology and Treatment of Osteoporosis. <i>Clinical Therapeutics</i> , 2015, 37, 1837-1850.	1.1	196
14	Cathepsin K Inhibitors for Osteoporosis: Biology, Potential Clinical Utility, and Lessons Learned. <i>Endocrine Reviews</i> , 2017, 38, 325-350.	8.9	193
15	Distribution of noncollagenous proteins in the matrix of adult human bone: Evidence of anatomic and functional heterogeneity. <i>Journal of Bone and Mineral Research</i> , 1993, 8, 1019-1029.	3.1	153
16	Secondary Fracture Prevention: Consensus Clinical Recommendations from a Multistakeholder Coalition. <i>Journal of Bone and Mineral Research</i> , 2020, 35, 36-52.	3.1	146
17	Hypoparathyroidism. <i>Nature Reviews Disease Primers</i> , 2017, 3, 17055.	18.1	142
18	Female reproductive system and bone. <i>Archives of Biochemistry and Biophysics</i> , 2010, 503, 118-128.	1.4	138

#	ARTICLE	IF	CITATIONS
19	Serum 25-Hydroxyvitamin D Levels: Variability, Knowledge Gaps, and the Concept of a Desirable Range. <i>Journal of Bone and Mineral Research</i> , 2015, 30, 1119-1133.	3.1	138
20	Identification of osteoclast-osteoblast coupling factors in humans reveals links between bone and energy metabolism. <i>Nature Communications</i> , 2020, 11, 87.	5.8	118
21	Understanding the Burden of Illness Associated with Hypoparathyroidism Reported Among Patients in the Paradox Study. <i>Endocrine Practice</i> , 2014, 20, 671-679.	1.1	108
22	Changes in quantitative bone histomorphometry in aging healthy men.. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1996, 81, 2264-2270.	1.8	93
23	Review of Hypoparathyroidism. <i>Frontiers in Endocrinology</i> , 2016, 7, 172.	1.5	88
24	Standards of care for hypoparathyroidism in adults: a Canadian and International Consensus. <i>European Journal of Endocrinology</i> , 2019, 180, P1-P22.	1.9	81
25	Clinical utility of serum sclerostin measurements. <i>BoneKEy Reports</i> , 2013, 2, 361.	2.7	78
26	Biomechanical Computed Tomography analysis (BCT) for clinical assessment of osteoporosis. <i>Osteoporosis International</i> , 2020, 31, 1025-1048.	1.3	68
27	Trends in subtrochanteric, diaphyseal, and distal femur fractures, 1984-2007. <i>Osteoporosis International</i> , 2012, 23, 1721-1726.	1.3	67
28	Recombinant Human Parathyroid Hormone Effect on Health-Related Quality of Life in Adults With Chronic Hypoparathyroidism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 722-731.	1.8	59
29	Bone metastases in thyroid cancer. <i>Journal of Bone Oncology</i> , 2020, 21, 100282.	1.0	59
30	Anti-sclerostin antibodies: Utility in treatment of osteoporosis. <i>Maturitas</i> , 2014, 78, 199-204.	1.0	58
31	Melorheostosis: a Rare Sclerosing Bone Dysplasia. <i>Current Osteoporosis Reports</i> , 2017, 15, 335-342.	1.5	55
32	Predictors of Bone Mineral Density in Aging Healthy Men Varies by Skeletal Site. <i>Calcified Tissue International</i> , 2002, 70, 137-145.	1.5	54
33	Bone biology, signaling pathways, and therapeutic targets for osteoporosis. <i>Maturitas</i> , 2015, 82, 245-255.	1.0	54
34	Comprehensive Assessment of Osteoporosis and Bone Fragility with CT Colonography. <i>Radiology</i> , 2016, 278, 172-180.	3.6	53
35	Hormonal regulation of biomineralization. <i>Nature Reviews Endocrinology</i> , 2021, 17, 261-275.	4.3	50
36	Validation of a CT-Derived Method for Osteoporosis Screening in IBD Patients Undergoing Contrast-Enhanced CT Enterography. <i>American Journal of Gastroenterology</i> , 2014, 109, 401-408.	0.2	49

#	ARTICLE	IF	CITATIONS
37	Epidemiology of Primary Hyperparathyroidism. <i>Journal of Clinical Densitometry</i> , 2013, 16, 8-13.	0.5	48
38	Effects of parathyroid hormone rhPTH(1-84) on phosphate homeostasis and vitamin D metabolism in hypoparathyroidism: REPLACE phase 3 study. <i>Endocrine</i> , 2017, 55, 273-282.	1.1	47
39	Safety and Efficacy of 5 Years of Treatment With Recombinant Human Parathyroid Hormone in Adults With Hypoparathyroidism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 5136-5147.	1.8	46
40	The role of biomineralization in disorders of skeletal development and tooth formation. <i>Nature Reviews Endocrinology</i> , 2021, 17, 336-349.	4.3	46
41	Prevalence of parathyroid carcinoma in 348 patients with multiple endocrine neoplasia type 1 – case report and review of the literature. <i>Clinical Endocrinology</i> , 2016, 84, 244-249.	1.2	44
42	Pharmacokinetics and Pharmacodynamics of Subcutaneous Recombinant Parathyroid Hormone (1-84) in Patients With Hypoparathyroidism: An Open-Label, Single-Dose, Phase I Study. <i>Clinical Therapeutics</i> , 2014, 36, 722-736.	1.1	43
43	Bone Histomorphometric Changes After Liver Transplantation for Chronic Cholestatic Liver Disease. <i>Journal of Bone and Mineral Research</i> , 2003, 18, 2190-2199.	3.1	41
44	MANAGEMENT OF ENDOCRINE DISEASE: Hypoparathyroidism in pregnancy: review and evidence-based recommendations for management. <i>European Journal of Endocrinology</i> , 2019, 180, R37-R44.	1.9	41
45	Teriparatide Therapy and Reduced Postoperative Hospitalization for Postsurgical Hypoparathyroidism. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2015, 141, 822.	1.2	26
46	Skeletal and extraskeletal disorders of biomineralization. <i>Nature Reviews Endocrinology</i> , 2022, 18, 473-489.	4.3	25
47	Epidemiology and Complications of Hypoparathyroidism. <i>Endocrinology and Metabolism Clinics of North America</i> , 2018, 47, 771-782.	1.2	24
48	Abaloparatide: Recombinant human PTHrP (1-34) anabolic therapy for osteoporosis. <i>Maturitas</i> , 2017, 97, 53-60.	1.0	23
49	Long-term outcomes in patients with multiple endocrine neoplasia type 1 and pancreaticoduodenal neuroendocrine tumours. <i>Clinical Endocrinology</i> , 2017, 86, 199-206.	1.2	23
50	Normocalcemic Hyperparathyroidism: A Heterogeneous Disorder Often Misdiagnosed?. <i>JBMR Plus</i> , 2020, 4, e10391.	1.3	23
51	PaTH Forward: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of TransCon PTH in Adult Hypoparathyroidism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e372-e385.	1.8	23
52	Bone Structural Characteristics and Response to Bisphosphonate Treatment in Children With Hajdu-Cheney Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 4163-4172.	1.8	22
53	Causes of low peak bone mass in women. <i>Maturitas</i> , 2018, 111, 61-68.	1.0	21
54	Bone disease in hypoparathyroidism. <i>Arquivos Brasileiros De Endocrinologia E Metabologia</i> , 2014, 58, 545-552.	1.3	20

#	ARTICLE	IF	CITATIONS
55	Asymptomatic Primary Hyperparathyroidism. <i>Frontiers of Hormone Research</i> , 2019, 51, 13-22.	1.0	20
56	Safety and Efficacy of Recombinant Human Parathyroid Hormone in Adults With Hypoparathyroidism Randomly Assigned to Receive Fixed 25- $\mu$ g or 50- $\mu$ g Daily Doses. <i>Clinical Therapeutics</i> , 2017, 39, 2096-2102.	1.1	18
57	Institutional Review Boards: What Clinician Researchers Need to Know. <i>Mayo Clinic Proceedings</i> , 2019, 94, 515-525.	1.4	17
58	RIP140 in monocytes/macrophages regulates osteoclast differentiation and bone homeostasis. <i>JCI Insight</i> , 2017, 2, e90517.	2.3	17
59	Basal ganglia calcification in hypoparathyroidism and pseudohypoparathyroidism: local and systemic metabolic mechanisms. <i>Journal of Endocrinological Investigation</i> , 2021, 44, 245-253.	1.8	14
60	Corticosteroid-Induced Osteoporosis. <i>American Journal of Clinical Dermatology</i> , 2012, 13, 167-190.	3.3	13
61	Transgender bone health. <i>Maturitas</i> , 2019, 127, 35-42.	1.0	12
62	Normocalcemic Primary Hyperparathyroidism: Need for a Standardized Clinical Approach. <i>Endocrinology and Metabolism</i> , 2021, 36, 525-535.	1.3	12
63	Oral bisphosphonate therapy and osteonecrosis of the jaw: what to tell the concerned patient. <i>International Journal of Prosthodontics</i> , 2007, 20, 115-22.	0.7	12
64	Is It Time to Stop (or Pause) Vertebral Augmentation?. <i>Journal of Bone and Mineral Research</i> , 2019, 34, 1-2.	3.1	10
65	Secondary Fracture Prevention: Consensus Clinical Recommendations from a Multistakeholder Coalition. <i>Journal of Orthopaedic Trauma</i> , 2020, 34, e125-e141.	0.7	10
66	Chronic Kidney Disease-Mineral and Bone Disorders (CKD-MBDs): What the Endocrinologist Needs to Know. <i>Endocrine Practice</i> , 2014, 20, 500-516.	1.1	9
67	Biochemical Testing Relevant to Bone. <i>Endocrinology and Metabolism Clinics of North America</i> , 2017, 46, 649-667.	1.2	9
68	25-Hydroxyvitamin D Levels and Acute Cellular Rejection in Liver Transplant Patients. <i>Endocrine Practice</i> , 2014, 20, 769-774.	1.1	8
69	Basal Ganglia Calcification Is Associated With Local and Systemic Metabolic Mechanisms in Adult Hypoparathyroidism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, 1900-1917.	1.8	7
70	Women With Chronic Hypoparathyroidism Have Low Risk of Adverse Pregnancy Outcomes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, 3312-3319.	1.8	7
71	New and emerging treatments for osteoporosis. <i>Clinical Endocrinology</i> , 2009, 71, 309-321.	1.2	6
72	Challenges in the management of chronic hypoparathyroidism. <i>Endocrine Connections</i> , 2020, 9, R229-R240.	0.8	6

#	ARTICLE	IF	CITATIONS
73	FGF23 Regulation of Phosphorus Homeostasis Is Dependent on PTH. <i>Endocrinology</i> , 2011, 152, 4016-4018.	1.4	5
74	Ethical Challenges in COVID-19 Biospecimen Research. <i>Mayo Clinic Proceedings</i> , 2021, 96, 165-173.	1.4	5
75	Glucocorticoid- and Transplantation-Induced Osteoporosis. <i>Endocrinology and Metabolism Clinics of North America</i> , 2021, 50, 251-273.	1.2	5
76	Epidemiology of Primary Hyperparathyroidism. , 2015, , 297-308.		4
77	A Lot of Progress, With More to Be Done: A Response to NIH Pathways to Prevention Report "Research Gaps for Long-Term Drug Therapies for Osteoporotic Fracture Prevention" <i>Journal of Bone and Mineral Research</i> , 2019, 34, 1549-1551.	3.1	4
78	Is Moderate Hypophosphatemia a New Indication for Surgery in Asymptomatic Primary Hyperparathyroidism?. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, , .	1.8	3
79	The PARADIGM (physicians advancing disease knowledge in hypoparathyroidism) registry for patients with chronic hypoparathyroidism: study protocol and interim baseline patient characteristics. <i>BMC Endocrine Disorders</i> , 2021, 21, 232.	0.9	3
80	Strontium. , 2020, , 652-665.		2
81	Premenopausal osteoporosis: Focus on the female athlete triad. <i>Case Reports in Women's Health</i> , 2021, 29, e00276.	0.2	2
82	Research Involving Participants With Impaired Consent Capacity. <i>Mayo Clinic Proceedings</i> , 2021, 96, 2806-2822.	1.4	2
83	Assessing the True Impact of Recurrent Fractures on Fracture Risk. <i>Journal of Bone and Mineral Research</i> , 2009, 24, 1512-1514.	3.1	1
84	Association of the serotonin transporter-linked polymorphic region genotype with lower bone mineral density. <i>Translational Psychiatry</i> , 2017, 7, e1213-e1213.	2.4	1
85	Hypoparathyroidism and Other Causes of Hypocalcemia. , 2019, , 192-203.		1
86	Does the use of proton-pump inhibitors increase the risk of fracture?. <i>Nature Clinical Practice Endocrinology and Metabolism</i> , 2007, 3, 564-565.	2.9	0
87	Mucocutaneous Manifestations of Endocrine Disorders. , 2014, , 206-225.		0
88	Reply to Corticosteroid-Induced Osteonecrosis in COVID-19: A Call for Caution. <i>Journal of Bone and Mineral Research</i> , 2020, 35, 2084-2085.	3.1	0
89	A bridge too far? Attempting to bridge the treatment gap in osteoporosis. <i>Endocrine</i> , 2020, 69, 241-243.	1.1	0
90	Stable interval bone density in patients with eosinophilic oesophagitis on topical steroids. <i>GastroHep</i> , 2020, 2, 272-280.	0.3	0